Wednesday, July 5th, 2017
If you’re watching TV tonight, you may see a familiar face. We are honored to announce that Dr. Neda Shamie will be the spokesperson in upcoming Restasis® television commercials.
As someone who previously suffered from dry eye symptoms , Dr. Shamie has been a Restasis user for the past five years. Dr. Shamie believes strongly in using the drops to treat and prevent worsening of the largely ignored problem of dry eyes. During her fellowship training, Dr. Shamie’s center played a pivotal role in evaluating the efficacy and utility of Restasis in treating chronic dry eyes due to lack of tear production and inflammation. As such, Dr. Shamie’s knowledge base in treating dry eyes and her passion for understanding and finding dry eye treatment options has flourished over the past decade.
Through the years, Dr. Shamie’s expertise and knowledge has enabled her to offer great relief to thousands of dry eye patients.
“RESTASIS®, is the prescription medication that is FDA-approved to help increase your eyes’ natural ability to produce tears, which may be reduced by inflammation due to Chronic Dry Eye disease It has truly been a centerpiece in my treatment protocols for my dry eye sufferers.” shared Dr. Shamie.
Through her work with Allergan and Restasis, Dr. Shamie hopes to increase awareness about dry eyes and spread the word nationally about this treatment option.
Tuesday, May 16th, 2017
What is corneal cross-linking?
Cross-linking is a procedure where UV light and riboflavin applied to the corneal surface strengthen collagen within the cornea. This helps to stabilize ectasia, a bulging of the eye’s surface, caused from progressive Keratoconus, other corneal disease or in rare complications of LASIK surgery.
Corneal cross-linking is a minimally invasive, in-office treatment for ectasia. In April of 2016, the U.S. Food and Drug Administration approved the corneal cross-linking as a means of treating patients with Keratoconus and ectasia.
Keratoconus is a progressive thinning and distortion of the cornea, that is vision threatening. It is the most common corneal dystrophy in the US, affecting approximately 170,000 people. Keratoconus changes the corneal curvature, resulting in blurred vision that is difficult to correct with spectacle lenses. This progressive thinning and weakening can result in significant visual loss and may lead to corneal transplants.
How does corneal cross-linking work?
In this procedure, the doctor applies a liquid form of vitamin B2 on the cornea and exposes it to ultraviolet light to strengthen the bonds of the cornea. This minimally invasive procedure works to shorten and thicken the collagen fibers, which stabilizes the thinning of the cornea and improves vision. The procedure does not require any surgical incisions, and corneal cross-linking may produce long-term and permanent results.
- makes new corneal collagen cross-links
- shortens and thickens collagen fibrils
- stiffens the cornea
At Advanced Vision Care, our doctors will complete an examination to determine whether you are a candidate for this procedure. With corneal cross-linking, we aim to restore and strengthen the vision of our patients who struggle with ectasia. We are committed to giving you individualized care that provides you with the clearest vision possible.
Monday, May 15th, 2017
Dr. Neda Shamie of Advanced Vision Care received the honor of presenting at the American Society of Cataract and Refractive (ASCRS) Annual Meeting last weekend. Dr. Shamie spoke on how the technology can help ophthalmology practices grow clinically, functionally, and financially.
She presented specifically on the Modernizing Medicine's ophthalmology suite and her experience with the electronic health record software. She discussed how the software allows for greater efficiency for the doctors and staff at Advanced Vision Care.
To read more about Dr. Shamie’s presentation, visit http://www.businesswire.com/news/home/20170505005605/en/Dr.-Neda-Shamie-Advanced-Vision-Care-Present
Sunday, May 14th, 2017
Los Angeles, CA – Doctors Samuel Masket, Nicole Fram and Neda Shamie of Advanced Vision Care, will present topics ranging from premium and complex cataract surgery techniques, advanced lens implant technology, artificial iris prosthesis, corneal crosslinking and innovative corneal transplant techniques at the American Society of Cataract and Refractive Surgery (ASCRS) Conference from May 5-8 th in Los Angeles.
The practice has been at the forefront of leading edge technology and clinical trials to advance visual outcomes for patients confronted with eye disease and poor vision.
Dr. Samuel Masket is the founding partner of Advanced Vision Care in Century City, Clinical Professor of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, UCLA, past-president of ASCRS and co- founder of the Samuel and Barbara Masket Foundation, a non-profit charitable trust to benefit patients in need of vision correcting surgery that they cannot otherwise afford. Dr. Masket is also credited for his pioneering work with the femtosecond laser in 2004 that helped lead to a revolutionary new method for cataract surgery. He will be presenting multiple courses and papers on complex cataract surgery, management of malpositioned IOLs and surgical solutions for Negative Dysphotopsia during the conference, as well as being the featured speaker of the named Richard L. Lindstrom, MD Lecture.
Dr. Nicole Fram is the managing partner at Advanced Vision Care in Century City, a Clinical Instructor of Ophthalmology, at the Stein Eye Institute, UCLA and has expertise in premium cataract surgery, anterior segment reconstruction, laser refractive surgery and cornea and external disease. She will be presenting at Cornea Day on implementing the newly FDA approved technique of Corneal Crosslinking into clinical practice. Corneal Crosslinking is indicated for progressive keratoconus or post-laser vision correction ectasia. This procedure can potentially prevent severe vision loss and eventual need for corneal transplantation in early identified and treated patients. In addition, she will be teaching several courses on subjects ranging from complex cataract surgery, management of malpositioned IOLs, astigmatism management, intraoperative aberrometry and innovative corneal transplantation techniques such as Descemet’s membrane Epithelial Keratoplasty (DMEK).
Dr. Neda Shamie has expertise in cornea and external disease, premium cataract surgery, anterior segment reconstruction and laser refractive surgery. She will be presenting at Cornea Day on endothelial keratoplasty and how to choose between DMEK and DSEK in complex cases. She will also be teaching several courses on topics such as optimizing results with laser cataract surgery, surgical correction of malpositioned IOLs in the setting of corneal disease, management of corneal astigmatism with cataract surgery, and diagnosis and treatment of dry eyes. She is recognized as a national and international expert in advanced corneal transplantation and a highly regarded educator of advanced surgical techniques. As such, she will be the lead instructor in a series of courses on the topic or corneal transplantation, including wet lab demonstrations on laser enabled Deep Anterior Lamellar Keratoplasty (DALK), Descemet’s Stripping Endothelial Keratoplasty (DSEK) and DMEK.
The ASCRS organization shares knowledge and skills with ophthalmic surgeons by providing clinical and practice management education and by working with patients, government, and the medical community to promote the delivery and advancement of high-quality eye care. Advanced Vision Care in Los Angeles, CA recognizes the benefits of sharing their surgeons’ experience with national and international colleagues to promote knowledge and treatments to correct vision disorders.
About Advanced Vision Care
Advanced Vision Care in Los Angeles, CA is dedicated to providing state-of- the-art, individually based, high quality, eye health care. Drs. Samuel Masket, Nicole Fram, Neda Shamie and Juliet Chung are board-certified skilled ophthalmologists that provide a variety of services to help patients attain the clearest vision possible. Their services cover a range of eye problems including cataracts, glaucoma, corneal disease and dry eye, retinal disorders, and ocular injuries. They have the common goal of ascertaining the most appropriate care for any given patient, explaining the purpose of the treatment, and in initiating said therapy in a courteous and compassionate manner irrespective of age, gender, nationality, race, or payment program. For more information on how to contribute to the Samuel and Barbara Masket Foundation, please visit the website www.masketfoundation.org.
Monday, February 27th, 2017
Do you experience eye dryness, irritation, or burning?
You may be eligible to participate in a research study to evaluate the safety and effectiveness of an investigational eye drop for the signs and symptoms of dry eye. Must be 19 Years or older and able to refrain from using your own eye drops and contact lenses during the study. For information, please contact Orly at 310-220-1220.
Friday, March 13th, 2015
Advanced Vision Care, a full service eye care center, today announced that it is the first in the local community to introduce a new treatment for patients who suffer from Evaporative Dry Eye disease. This disease stems from a deficiency in the oily lipid layer of the eye’s natural tear film. The oily lipids serve as a protective layer so that the aqueous (water) layer of the eye’s tear film does not evaporate. Advanced Vision Care has introduced a new, advanced in-office treatment, called LipiFlow®, which is intended to treat patients with blocked meibomian glands, called meibomian gland dysfunction, by unblocking the glands and allowing them to resume the secretion of oily lipids needed for a healthy tear film.
Dry eye disease affects more than 100 million people worldwide. Of those, 65 percent suffer from Evaporative Dry Eye. Common symptoms of dry eye include dryness, grittiness, soreness, irritation, burning and eye fatigue. These symptoms can hinder people’s daily activities such as reading, using the computer, wearing contact lenses and being outdoors on windy days. Many dry eye patients complain those symptoms worsen throughout the day. “Dry eye disease is one of the most common topics patients discuss when visiting eye care professionals,” said Dr. Nicole Fram. “We are very pleased to introduce the new LipiFlow treatment to help those patients who are very frustrated with this chronic disease and all of the ways it negatively impacts their lives. In effect, LipiFlow helps the meibomian glands resume their natural function and many patients note symptom relief.”
Historically, common therapies aimed at dry eye symptom relief included using warm compresses, over- the-counter wetting drops and ointments, and prescription drugs. Alternatively, the new LipiFlow treatment addresses the root cause of evaporative dry eye by unblocking the meibomian glands that secrete oily lipids. In controlled clinical studies of patients who received a single LipiFlow treatment, the average meibomian gland score at 4 weeks increased by two to three times over the baseline condition, which reflects improvement in the number of glands secreting and secretion quality.
Thursday, September 29th, 2011